User login
The second day of the Avastin hearing at the Food and Drug Administration has started. Following the FDA's presentation yesterday, representatives for Genentech will argue why the drug should be approved for breast cancer treatment. Following a question-and-answer session, the FDA's independent advisory board will announce its vote this afternoon.
Naseem S. Miller and Elizabeth Mechcatie contributed to this report.
The second day of the Avastin hearing at the Food and Drug Administration has started. Following the FDA's presentation yesterday, representatives for Genentech will argue why the drug should be approved for breast cancer treatment. Following a question-and-answer session, the FDA's independent advisory board will announce its vote this afternoon.
Naseem S. Miller and Elizabeth Mechcatie contributed to this report.
The second day of the Avastin hearing at the Food and Drug Administration has started. Following the FDA's presentation yesterday, representatives for Genentech will argue why the drug should be approved for breast cancer treatment. Following a question-and-answer session, the FDA's independent advisory board will announce its vote this afternoon.
Naseem S. Miller and Elizabeth Mechcatie contributed to this report.